Claims

1. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof for use in the long-term treatment of a CNS disease in a patient, wherein said treatment is associated with little or no weight gain.

2. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof for use in the treatment of a CNS disease in a patient who has previously received medication (or is still receiving it) for the treatment of said disease which medication was ceased (or has to be ceased) due to weight related adverse events.

3. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof use in the treatment of a CNS disease in a patient who is overweight.

4. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof according to claim 3, wherein said patient is characterised by a BMI above 25.

5. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof for use in the treatment of a CNS disease in a patient who also suffers from a disease where weight increase should be avoided.

6. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof according to claim 5, wherein said patient also suffers from type II diabetes, hypertension or coronary heart diseases, or is abstaining from nicotine.

7. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof according to any of claims 1-6, wherein said CNS disease is selected from depression, anxiety, chronic pain and abuse.

8. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof according to any of claims 1-7 which is the hydrobromide salt.

9. A method of promoting the sales of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof, said method comprising the public distribution of the information that administration of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof to a patient is not unfavourably associated with weight gain or that the administration of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof to a patient is not or only to limited extent associated with weight gain.

10. The method according to claim 9, wherein said pharmaceutically acceptable salt is the hydrobromide salt.

11. Use of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the long-term treatment of a CNS disease wherein said treatment is not associated with weight gain.

12. Use of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of a CNS disease in a patient who has previously received medication (or is still receiving it) for the treatment of said disease which medication was ceased (or has to be ceased) due to weight related adverse events.

13. Use of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of a CNS disease in a patient who is overweight.

14. The use according to claim 13 wherein said patient is characterised by a BMI above 25.

15. Use of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of a CNS disease in a patient who suffers from a further disease where weight increase should be avoided.

16. The use according to claim 15 wherein said further disease is selected from type II diabetes, hypertension and coronary heart diseases, or wherein said patient is abstaining from nicotine.

17. The use according to any of claims 11-16, wherein said CNS disease is selected from depression, anxiety, chronic pain and abuse.

18. The use according to any of claims 11-17, wherein said pharmaceutically acceptable salt is the hydrobromide salt.

Claims

1. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof for use in the treatment of depression or anxiety disease in a patient who has previously received medication (or is still receiving it) for the treatment of said disease which medication was ceased (or has to be ceased) due to weight related adverse events.

2. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof according to claim 1 which is the hydrobromide salt.

3. Use of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of depression or anxiety in a patient who has previously received medication (or is still receiving it) for the treatment of said disease which medication was ceased (or has to be ceased) due to weight related adverse events.

4. The use according to claim 3, wherein said pharmaceutically acceptable salt is the hydrobromide salt.